Psoriatic arthritis (PsA) often develops in patients with psoriasis, making it a key model for studying joint disease in its pre-clinical stages and exploring prevention strategies. Shared immunopathology between skin and joints supports the idea that treating psoriasis—especially with biologics—may help prevent PsA, though findings on the effectiveness of TNF inhibitors have been mixed. This review examines current challenges in early PsA, including evolving nomenclature, risk factors, and the potential for disease interception before clinical onset.

Reference: López-Medina C, McGonagle D, Gossec L. Subclinical psoriatic arthritis and disease interception-where are we in 2024? Rheumatology (Oxford). 2025 Jan 1;64(1):56-64. doi: 10.1093/rheumatology/keae399. PMID: 39150442; PMCID: PMC11701312.